Antero Midstream Corporation logo AM - Antero Midstream Corporation

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 1
HOLD 12
SELL 4
STRONG
SELL
0
| PRICE TARGET: $24.00 DETAILS
HIGH: $24.00
LOW: $24.00
MEDIAN: $24.00
CONSENSUS: $24.00
UPSIDE: 6.24%

Stock News

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001).

May 14, 2026 03:30 AM prnewswire.com
Antero Resources Announces First Quarter 2026 Earnings Release Date and Conference Call

Antero Resources Announces First Quarter 2026 Earnings Release Date and Conference Call

DENVER, April 15, 2026 /PRNewswire/ -- Antero Resources (NYSE: AR) ("Antero" or the "Company") today announced that the Company plans to issue its first quarter 2026 earnings release on Wednesday, April 29, 2026 after the close of trading on the New York Stock Exchange. A conference call is scheduled on Thursday, April 30, 2026 at 9:00 am MT to discuss the financial and operational results.

Apr 15, 2026 12:15 PM prnewswire.com

Price Targets